AstraZeneca’s published Q4 earnings have shown better than expected results, with new launches and commercial execution delivering full-year sales growth and a very strong final quarter.Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.